Genocea to Host Virtual R&D Day on December 14th, 2016
December 08 2016 - 7:00AM
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical
company developing T cell-directed vaccines and immunotherapies,
will host a virtual Research and Development (R&D) Day for
analysts, investors and media on Wednesday, December 14, 2016,
starting at 8:30 a.m. ET. This event will be available via webcast
and conference call only.
During the virtual R&D Day, members of the Genocea
leadership team and leading physicians will provide a comprehensive
overview of lead product candidate GEN-003 for the treatment of
genital herpes, which is expected to enter Phase 3 development in
2017, and share how the Company is applying its unique and
proprietary T cell antigen identification platform, ATLAS™, to
immuno-oncology and cancer vaccine development.
Webcast & Conference Call InformationA live
webcast of the R&D Day can be accessed by visiting the “Events
and Presentations” tab of the investor relations section of the
Genocea website at http://ir.genocea.com. A replay of the webcast
will be archived for 30 days following the presentation.
Interested participants and investors may also join the event by
conference call by dialing (800) 708-4540 (domestic) or (847)
619-6397 (international) and referencing the conference ID
43927983.
About Genocea Biosciences Inc.Genocea is
harnessing the power of T cell immunity to develop life-changing
vaccines and immunotherapies. T cells are increasingly recognized
as a critical element of protective immune responses to a wide
range of diseases, but traditional discovery methods have proven
unable to identify the targets of such protective immunity. Using
ATLAS™, its proprietary technology platform, Genocea identifies
these targets to potentially enable the rapid development of
medicines to address critical patient needs. Genocea’s pipeline
includes GEN-003, a novel T cell-enabled immunotherapy for genital
herpes in Phase 2 clinical development, and earlier-stage
investments in immuno-oncology. For more information, please visit
the company's website at www.genocea.com.
For media:
Liz Bryan
Spectrum Science Communications, Inc.
O: 202-955-6222
lbryan@spectrumscience.com
For investors:
Jonathan Poole
Genocea Biosciences, Inc.
O: 617-876-8191
jonathan.poole@genocea.com
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From Apr 2024 to May 2024
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Genocea Biosciences Inc (NASDAQ): 0 recent articles
More News Articles